Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

More about CML Microsystems. CML Microsystems Plc develops mixed-signal, RF, and microwave semiconductors for global comm ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

A study from a major cancer center collected data on 2857 patients with Ph+ CML, most of whom were White and middle-aged. Ten-year overall survival for patients with Ph+ CML treated since 2000 was ...

In October 2025, Terns Pharmaceuticals announced strongly positive Phase 1 data for TERN-701 in chronic myeloid leukemia, with a 75% major molecular response rate by 24 weeks and no dose-limiting ...

The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

Investing.com -- Terns Pharmaceuticals (NASDAQ:TERN) stock surged 28% Tuesday, extending its two-day gain to 120% following positive clinical data for its TERN-701 treatment in relapsed/refractory ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Terns Pharmaceuticals (TERN) is getting attention after announcing that early-stage trial results for its CML drug candidate, TERN-701, were selected for oral presentation at this year's American ...

The Columbus Metropolitan Library purchases over 400,000 books per year for its 23 branches in Franklin County.